AI drug-discovery firm Insilico Medicine and Taiwan-based contract manufacturer Bora Pharmaceuticals are launching a new company built around an AI-driven biologics manufacturing platform.
According to Fierce Pharma, the tie-up is a $2.5 billion AI drug discovery deal that links Insilico — described as a "red-hot" generative AI specialist — with Bora, a major contract development and manufacturing organization, or CDMO. A CDMO is a company that other drugmakers hire to develop and produce their medicines, rather than building factories of their own.
Endpoints News reports that the two companies are creating the new venture specifically to compete with drug-manufacturing service providers headquartered in China. The platform focuses on biologics — complex, protein-based drugs grown in living cells, which are harder and costlier to make than conventional chemical pills.
Insilico has drawn attention for using generative AI to speed up the earliest stages of finding new drug candidates. Pairing that with Bora's manufacturing muscle points to an ambition that runs from drug design all the way through to production, with AI woven into how the medicines are actually made.
The sources here confirm the partners, the reported deal value, the biologics-manufacturing focus, and the stated goal of challenging China-based rivals; further specifics of the new company were not detailed in the items reviewed.
Why it matters: it is an early sign that the AI boom in pharma is moving beyond discovering drugs toward manufacturing them, and it sets up a fresh competitor to the Chinese contract manufacturers that much of the industry now depends on.